Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab

Withdrawal of a first-line DMD after prolonged treatment in middle-aged MS patients with stable disease appears to be relatively safe, while natalizumab withdrawal in a similar group of patients cannot be safely done without starting alternative therapy.